immunotherapy

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3,…

10 months ago

Kanazawa University research: New Breakthrough in Cancer Treatment: Tiny Vesicles Help the Immune System Fight Tumors

KANAZAWA, Japan, April 3, 2025 /PRNewswire/ -- Scientists at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University and colleagues have developed a…

10 months ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of…

10 months ago

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif.,…

10 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts--(Newsfile…

10 months ago

Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research

Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL,…

10 months ago

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

11 months ago

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company…

11 months ago

Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28,…

11 months ago

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative…

11 months ago